elafibranor

Drug Overview

ELAFIBRANOR, containing the active ingredient of the same name, is a breakthrough therapeutic agent in the Hepatology and Gastroenterology fields. It belongs to the Drug Class of PPAR AGONISTS (specifically a dual Peroxisome Proliferator-Activated Receptor alpha/delta agonist). This medication is a first-in-class Targeted Therapy designed to modulate the metabolic and inflammatory pathways involved in chronic liver disease.

In the clinical landscape, Elafibranor represents a significant advancement for patients with Primary Biliary Cholangitis (PBC) who have an inadequate response to first-line therapy. By targeting specific nuclear receptors, it reduces the accumulation of toxic bile acids and calms the immune-mediated destruction of the bile ducts. In international clinical protocols, it is valued for its ability to promote Mucosal Healing of the biliary epithelium and stabilize the liver’s biochemical profile.

• Generic Name: Elafibranor
• US Brand Names: Iqirvo
• Route of Administration: Oral (Tablets)
• FDA Approval Status: FDA-approved (Accelerated Approval in 2024) for the treatment of Primary Biliary Cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.

What Is It and How Does It Work? (Mechanism of Action)

The efficacy of Elafibranor is due to its dual activation of PPAR \alpha  and PPAR \delta  receptors, which coordinate a multi-pronged defense against liver injury.

1. Dual PPAR Alpha/Delta Activation

At the molecular level, Elafibranor acts as a ligand for nuclear receptors.

• PPAR \alpha  Activation: Increases the expression of genes involved in bile acid detoxification and transport. This helps “pump” toxic bile acids out of the liver cells.
• PPAR \delta  Activation: Exerts potent anti-inflammatory effects by inhibiting the pro-inflammatory pathways (like NF-κ (Kappa)B) that lead to biliary scarring (fibrosis).

2. Reduction of Cholestatic Injury

By improving the flow and composition of bile, Elafibranor reduces the “detergent-like” damage that bile acids cause to the Intestinal Epithelial Barrier and the biliary tree. This reduction in cholestasis (bile backup) prevents the “leaking” of liver enzymes into the bloodstream and slows the progression toward cirrhosis.

3. Metabolic Stabilization

Elafibranor also improves lipid metabolism and insulin sensitivity. In the context of PBC, this metabolic support helps maintain the energy balance of hepatocytes (liver cells), supporting overall Mucosal Healing and structural integrity of the liver tissue.

FDA-Approved Clinical Indications

Primary Indication

The primary FDA-approved use for Elafibranor is:

• Primary Biliary Cholangitis (PBC): Long-term management of PBC in adults who have not reached target alkaline phosphatase (ALP) levels with standard UDCA therapy, or those who cannot tolerate UDCA.

Other Approved & Off-Label Uses

• NASH / MASH (Research/Off-label): Extensively studied for Non-Alcoholic Steatohepatitis. While it did not meet all primary endpoints for NASH in earlier trials, research continues into its role in metabolic-associated liver disease.
• Primary Sclerosing Cholangitis (PSC) (Off-label): Investigated for its ability to reduce biliary inflammation in other cholestatic conditions.
• Dyslipidemia (Off-label): Utilizing its PPAR \alpha  effects to improve triglyceride and cholesterol profiles.

Primary Gastroenterology Indications

• Biochemical Response Restoration: Lowering Alkaline Phosphatase (ALP) and Bilirubin to levels that correlate with improved long-term survival.
• Anti-Fibrotic Support: Slowing the deposition of collagen and scar tissue in the liver.
• Biliary Epithelial Protection: Stabilizing the cells that line the bile ducts to prevent further immune-mediated “ductopenia” (loss of ducts).

Dosage and Administration Protocols

Elafibranor is a once-daily oral medication that provides a steady-state concentration to maintain nuclear receptor activation.

Dosage Adjustments and Specific Populations

• Renal Impairment: Not recommended in patients with severe renal impairment (eGFR < 30 mL/min) or end-stage renal disease.
• Hepatic Impairment: Avoid use in patients with decompensated cirrhosis (e.g., Child-Pugh Class B or C).
• Pediatric Use: Safety and efficacy have not been established in children.
• Vigilance: Monitoring of muscle enzymes (Creatine Kinase) is recommended, as PPAR agonists can occasionally impact muscle tissue.

“Dosage must be individualized by a qualified healthcare professional.”

Clinical Efficacy and Research Results

Clinical trials (including the pivotal ELATIVE study) confirm that Elafibranor provides a superior biochemical response compared to placebo.

• ALP Reduction Success: In phase 3 trials, approximately 51% of patients achieved the primary biochemical endpoint (ALP < 1.67x upper limit of normal) compared to only 4% in the placebo group.
• Bilirubin Stabilization: Research indicates that Elafibranor effectively normalizes total bilirubin in a significant percentage of patients, a key predictor of liver transplant-free survival.
• Pruritus (Itching) Impact: Clinical data suggests a trend toward improvement in cholestatic pruritus, a debilitating symptom of PBC, likely due to the reduction in systemic bile acid levels.
• Safety Durability (2025): Long-term extension data (2024–2026) confirms that the biochemical improvements are sustained over 2 years of continuous therapy.

Safety Profile and Side Effects

Elafibranor is generally well-tolerated, but it requires regular monitoring of kidney and muscle markers.

Common Side Effects (>10%)

• Weight Gain: A known effect of PPAR modulation.
• Abdominal Pain: Usually mild and transient.
• Nausea / Vomiting: Reported in the early stages of therapy.
• Diarrhea: Due to changes in bile acid composition.

Serious Adverse Events

• Serum Creatinine Increase: PPAR agonists can cause a reversible increase in creatinine; kidney function must be monitored.
• Myopathy / Rhabdomyolysis: Rare muscle breakdown; patients should report unexplained muscle pain.
• Bone Fractures: A potential risk associated with long-term PPAR \delta  activation.
• Hepatotoxicity: While it treats liver disease, paradoxical “drug-induced liver injury” is a remote possibility with any new Small Molecule therapy.

Management Strategies

Patients should have baseline blood work (ALP, Bilirubin, Creatinine, CK) before starting therapy. Vigilance is required regarding the “Child-Pugh” status; if a patient shows signs of liver failure (jaundice, ascites), the drug should be discontinued.

Research Areas

Current Research Areas focus on “Biliary Immunology” and the Gut-Liver Axis.

Recent research (2024–2026) is investigating how Elafibranor impacts the Gut Microbiome. Since bile acids act as “regulators” of intestinal bacteria, altering bile flow with a PPAR agonist may improve the Intestinal Epithelial Barrier health and reduce the translocation of bacteria to the liver.

Other trials are evaluating the impact of Elafibranor on Mucosal Immunology, specifically whether it reduces the activation of “Th17 cells” in the bile ducts. Researchers are also studying “Combination Targeted Therapy”—pairing Elafibranor with newer “FXR agonists” to achieve total biochemical normalization in refractory PBC cases.

Disclaimer: Research regarding the specific reduction of “Th17 cell” activation in the bile ducts and the use of Elafibranor to modulate the Gut-Liver Axis via microbiome alterations is currently in the investigative phase and is not yet standard clinical practice. 

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: Recent ALP, Bilirubin, and GGT levels.
• Organ Function: Review baseline serum Creatinine and eGFR.
• Specialized Testing: Liver stiffness measurement (FibroScan) to document baseline fibrosis.
• Screening: Rule out decompensated cirrhosis (ascites, varices, or encephalopathy).

Monitoring and Precautions

• Vigilance: Monitor ALP and Bilirubin every 3 months.
• Kidney Health: Check Creatinine 1 month after starting, then periodically.
• Lifestyle: Advise the patient that PBC is a chronic condition; Elafibranor is not a “cure” but a tool to prevent liver failure.

“Do’s and Don’ts” List

• DO take your pill at the same time every day to maintain steady levels.
• DO notify your doctor immediately if you develop dark urine or yellowing of the eyes.
• DON’T stop your UDCA (Ursodiol) unless specifically instructed by your hepatologist.
• DON’T start new herbal supplements without checking for potential liver interactions.

Legal Disclaimer

This guide is for informational purposes only and does not replace professional medical advice, diagnosis, or treatment from a qualified healthcare provider. Always seek the advice of your physician or other qualified health practitioner with any questions you may have regarding a medical condition or the use of medications. Never disregard professional medical advice or delay in seeking it because of something you have read in this document.